Company intelligence / Profile preview

Miist Therapeutics

Alameda, California, United Statesmiisttherapeutics.com ↗

Ownership: Private
Employees: ~3
Development stage: Phase 1

Overview

Phase I trial showed that smokers who used Miist's inhaler eliminated 92% of their cravings in only two minutes, which is a 10X improvement over existing standard of care[6]. The company is preparing for Phase II trials for its smoking cessation technology[6].

Therapeutic areas: PsychiatryNeurology
Modalities: Inhaled therapies
Industry: Biotech

Drug pipeline

1 asset

MST-02

Preclinical

Beyond the preview

Go deeper on Miist Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Miist Therapeutics.

Explore the full profile